cbdMD, Inc. Regains Compliance with NYSE American Listing Standards

Rhea-AI Summary

cbdMD (NYSE American: YCBD) announced it has regained full compliance with NYSE American listing standards and that the “.BC” noncompliance indicator was removed effective at the open of trading on December 8, 2025. The NYSE American notified the company on December 5, 2025 that cbdMD resolved deficiencies under Sections 1003(a)(i) and (ii) of the NYSE American Company Guide.

Management highlighted the May Series A Preferred share conversion and a capital raise completed in September as key elements of the company’s compliance plan. cbdMD said it will remain subject to NYSE American continued listing monitoring procedures and will file a Form 8-K with the SEC on December 8, 2025 for additional details.

Positive

• NYSE compliance regained with ".BC" indicator removed effective Dec 8, 2025
• Regulatory confirmation from NYSE American letter dated Dec 5, 2025
• Capital actions — Series A Preferred conversion (May) and capital raise (Sept) aided compliance

Negative

• Ongoing monitoring — remains subject to NYSE American continued listing procedures

Key Figures

NYSE American sections Sections 1003(a)(i) and (ii) Deficiencies resolved for continued listing compliance

Compliance confirmation date December 5, 2025 Date of NYSE American letter confirming compliance

Compliance effective date December 8, 2025 Date .BC indicator removed and full compliance effective

Form 8-K filing date December 8, 2025 Planned SEC filing for compliance announcement

Market Reality Check

$0.6100 Last Close

Volume Volume 155,063 is well below the 20-day average of 1,008,540 (relative volume 0.15). low

Technical Price at $0.61 is below the $1.23 200-day MA and 90.67% below the 52-week high, but 29.76% above the 52-week low.

Peers on Argus 1 Down

Pre-news, YCBD was roughly flat over 24 hours (-0.23%) while only one scanned peer, FLGC, showed momentum with a -6.40% move and no news, suggesting stock-specific rather than sector-driven dynamics.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 21	Prelim FY2025 results	Neutral	-6.7%	Preliminary FY2025 and Q4 net sales with improved net loss guidance.
Nov 21	Prelim FY2025 results	Neutral	-6.7%	Repeat report of preliminary FY2025 results and loss improvement details.
Oct 22	Product expansion	Positive	-5.7%	Launch of two new 10mg Herbal Oasis THC-infused social seltzer flavors.
Oct 09	Distribution partnership	Positive	+1.4%	Bevtalk partnership to expand Herbal Oasis distribution across Florida.
Oct 09	Distribution partnership	Positive	+1.4%	Duplicate report of Florida distribution rollout via Bevtalk.

Pattern Detected

Recent history shows a tendency for negative reactions to financial and product news, with only modest gains on distribution partnerships, indicating occasional divergence between seemingly constructive updates and price moves.

Recent Company History

Over the last few months, cbdMD reported preliminary fiscal 2025 results on Nov 21, 2025, indicating slightly lower full-year net sales but a meaningfully improved net loss, yet the stock fell about 6.67%. Product-focused news on Oct 22, 2025 about expanding the Herbal Oasis THC seltzer lineup also saw a -5.66% move. A distribution partnership announcement on Oct 9, 2025 produced a smaller 1.4% gain, showing mixed but often cautious market responses to company updates.

Market Pulse Summary

This announcement confirms that cbdMD regained full compliance with NYSE American continued listing standards, resolving Section 1003(a)(i) and (ii) deficiencies as of December 8, 2025. It follows balance sheet actions such as preferred share conversion and a capital raise referenced by management. Investors may focus on upcoming SEC disclosures, governance practices, and whether recent financial and product initiatives translate into more durable operating performance.

Key Terms

continued listing standards regulatory

"regained full compliance with the continued listing standards of the NYSE American"

Ongoing rules a stock exchange requires a listed company to meet to keep its shares trading publicly, such as minimum share price, market value, timely financial reports, and governance practices. Think of it as a membership checklist for a club: falling short can lead to warnings or removal from the exchange, which can sharply reduce liquidity, investor confidence, and a stock’s value. Investors watch these standards to gauge regulatory risk and the stability of their holdings.

series a preferred financial

"We believe our successful Series A Preferred share conversion in May"

Series A preferred is an early round of equity that gives certain investors a special class of shares with priority rights over common shareholders, such as first claim on assets or dividends and often the option to convert into common stock later. Think of it like a VIP ticket at a concert that guarantees earlier entry and some extra perks; for investors it reduces risk, defines ownership stakes, and affects control and potential returns in future sales or public offerings.

form 8-k regulatory

"please refer to the Company's Form 8-K to be filed with the Securities"

A Form 8-K is a report that companies file with the government to share important news quickly, such as changes in leadership, major business deals, or financial updates. It matters because it helps investors stay informed about significant events that could affect the company's value or stock price.

AI-generated analysis. Not financial advice.

CHARLOTTE, N.C., Dec. 8, 2025 /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), a leading innovator in wellness and hemp-derived products, is pleased to announce that it has regained full compliance with the continued listing standards of the NYSE American. As a result, the ".BC" indicator has been removed from the list of noncompliant issuers effective at the open of trading, December 8, 2025.

The NYSE American formally notified the Company in a letter dated December 5, 2025, confirming that cbdMD has resolved all deficiencies related to Sections 1003(a)(i) and (ii) of the NYSE American Company Guide.

"We are excited to share this important news with our shareholders, partners, and team. Preserving our NYSE American listing was a critical achievement and reflects the tremendous work completed this year to strengthen our balance sheet and position the Company for sustainable growth," said Ronan Kennedy, cbdMD's CEO. "We believe our successful Series A Preferred share conversion in May and capital raise completed in September were essential components of our compliance strategy and demonstrated the commitment of our investors and stakeholders to cbdMD's long-term vision. We appreciate the NYSE American for their constructive engagement throughout this process, and we look forward to continuing to build long-term value for our shareholders as we move ahead."

The Company will remain subject to NYSE American's continued listing monitoring procedures and remains committed to maintaining strong financial discipline and governance going forward.

For additional information, please refer to the Company's Form 8-K to be filed with the Securities and Exchange Commission on December 8, 2025.

About cbdMD, Inc. 

cbdMD, Inc. is one of the leading and most highly trusted and most recognized cannabidiol (CBD) brands with a comprehensive line of U.S. produced, CBD products, and an array of Farm Act compliant Delta 9 products. Our Paw CBD brand of pet products includes veterinarian-formulated products, our Herbal Oasis THC Seltzer brand and our ATRx brand of natural functional mushroom support. To learn more about cbdMD and our comprehensive line of U.S. grown hemp products as well as our other brands, please visit www.cbdmd.com , www.pawcbd.com, www.herbaloasis.com, or ATRxlabs.com , follow cbdMD on Instagram and Facebook, or visit one of the thousands of retail outlets that carry cbdMD's products. 

Forward-Looking Statements 

This press release includes forward-looking statements within the meaning of U.S. federal securities laws. Forward-looking statements reflect management's current expectations and assumptions regarding future events and performance, and they involve risks and uncertainties. Actual results may differ materially from those expressed or implied in these statements due to various factors, including but not limited to compliance with continued NYSE American listing requirements and risks disclosed in the Company's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update any forward-looking statements, except as required by applicable law.

Contact Information:

cbdMD, Inc.
Ronan Kennedy
Chief Executive Officer and Chief Financial Officer
IR@cbdmd.com
(704) 445-3064

View original content to download multimedia:https://www.prnewswire.com/news-releases/cbdmd-inc-regains-compliance-with-nyse-american-listing-standards-302635518.html

SOURCE cbdMD, Inc.

FAQ

What did cbdMD (YCBD) announce about NYSE American compliance on December 8, 2025?

cbdMD announced it regained full NYSE American compliance and the ".BC" noncompliance indicator was removed effective at the open of trading on Dec 8, 2025.

When did the NYSE American notify cbdMD (YCBD) that deficiencies were resolved?

The NYSE American notified cbdMD in a letter dated Dec 5, 2025 that Sections 1003(a)(i) and (ii) deficiencies were resolved.

Which corporate actions did cbdMD (YCBD) cite as part of its compliance strategy?

cbdMD cited a Series A Preferred share conversion in May 2025 and a capital raise completed in September 2025 as key components of its compliance strategy.

Will cbdMD (YCBD) still be monitored by the exchange after regaining compliance?

Yes. The company stated it will remain subject to NYSE American's continued listing monitoring procedures going forward.

Where can investors find more details about cbdMD's (YCBD) compliance update filed Dec 8, 2025?

Investors can review the company's Form 8-K filed with the SEC on Dec 8, 2025 for additional details.